Literature DB >> 16132363

Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.

Christopher P Landowski1, Xueqin Song, Philip L Lorenzi, John M Hilfinger, Gordon L Amidon.   

Abstract

PURPOSE: The aim of this study was to synthesize amino acid ester prodrugs of 5-fluoro-2'-deoxyuridine (floxuridine) to enhance intestinal absorption and resistance to glycosidic bond metabolism.
METHODS: Amino acid ester prodrugs were synthesized and examined for their hydrolytic stability in human plasma, in Caco-2 cell homogenates, and in the presence of thymidine phosphorylase. Glycyl-L: -sarcosine uptake inhibition and direct uptake studies with HeLa/PEPT1 cells [HeLa cells overexpressing oligopeptide transporter (PEPT1)] were conducted to determine PEPT1-mediated transport and compared with permeability of the prodrugs across Caco-2 monolayers.
RESULTS: Isoleucyl prodrugs exhibited the highest chemical and enzymatic stability. The prodrugs enhanced the stability of the glycosidic bond of floxuridine. Thymidine phosphorylase rapidly cleaved floxuridine to 5-fluorouracil, whereas with the prodrugs no detectable glycosidic bond cleavage was observed. The 5'-L: -isoleucyl and 5'-L: -valyl monoester prodrugs exhibited 8- and 19-fold PEPT1-mediated uptake enhancement in HeLa/PEPT1 cells, respectively. Uptake enhancement in HeLa/PEPT1 cells correlated highly with Caco-2 permeability for all prodrugs tested. Caco-2 permeability of 5'-L: -isoleucyl and 5'-L: -valyl prodrugs was 8- to 11-fold greater compared with floxuridine.
CONCLUSIONS: Amino acid ester prodrugs such as isoleucyl floxuridine that exhibit enhanced Caco-2 transport and slower rate of enzymatic activation to parent, and that are highly resistant to metabolism by thymidine phosphorylase may improve oral delivery and therapeutic index of floxuridine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132363     DOI: 10.1007/s11095-005-6156-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Authors:  Duxin Sun; Hans Lennernas; Lynda S Welage; Jeffery L Barnett; Christopher P Landowski; David Foster; David Fleisher; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

2.  STUDIES OF FLUORINATED PYRIMIDINES. XVIII. THE DEGRADATION OF 5-FLUORO-2'-DEOXYURIDINE AND RELATED COMPOUNDS BY NUCLEOSIDE PHOSPHORYLASE.

Authors:  G D BIRNIE; H KROEGER; C HEIDELBERGER
Journal:  Biochemistry       Date:  1963 May-Jun       Impact factor: 3.162

3.  Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations.

Authors:  E HARBERS; N K CHAUDHURI; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1959-05       Impact factor: 5.157

4.  A photoactivated prodrug.

Authors:  Y Wei; Y Yan; D Pei; B Gong
Journal:  Bioorg Med Chem Lett       Date:  1998-09-22       Impact factor: 2.823

5.  A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.

Authors:  Insook Kim; Xueqin Song; Balvinder S Vig; Sachin Mittal; Ho-Chul Shin; Philip J Lorenzi; Gordon L Amidon
Journal:  Mol Pharm       Date:  2004 Mar-Apr       Impact factor: 4.939

6.  A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.

Authors:  Teresa N Faria; Julita K Timoszyk; Terry R Stouch; Balvinder S Vig; Christopher P Landowski; Gordon L Amidon; C David Weaver; Doris A Wall; Ronald L Smith
Journal:  Mol Pharm       Date:  2004-01-12       Impact factor: 4.939

7.  Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.

Authors:  S C Tobias; R F Borch
Journal:  J Med Chem       Date:  2001-12-06       Impact factor: 7.446

8.  Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.

Authors:  M E Ganapathy; W Huang; H Wang; V Ganapathy; F H Leibach
Journal:  Biochem Biophys Res Commun       Date:  1998-05-19       Impact factor: 3.575

9.  Determinants of 5-fluorouracil sensitivity in human tumors.

Authors:  R G Moran; C Heidelberger
Journal:  Bull Cancer       Date:  1979       Impact factor: 1.276

10.  Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.

Authors:  H K Han; D M Oh; G L Amidon
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

View more
  19 in total

1.  Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

Review 2.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

3.  Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2011-06-14       Impact factor: 4.200

4.  The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.

Authors:  Yasuhiro Tsume; Chester J Provoda; Gordon L Amidon
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-03-05       Impact factor: 3.205

5.  Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.

Authors:  Thulani H Senanayake; Galya Warren; Xin Wei; Serguei V Vinogradov
Journal:  J Control Release       Date:  2013-02-04       Impact factor: 9.776

6.  Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.

Authors:  Jing Sun; Arik Dahan; Gordon L Amidon
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

Review 7.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.

Authors:  Yasuhiro Tsume; Tuba Incecayir; Xueqin Song; John M Hilfinger; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2013-12-19       Impact factor: 5.571

9.  Design and synthesis of vidarabine prodrugs as antiviral agents.

Authors:  Wei Shen; Jae-Seung Kim; Phillip E Kish; Jie Zhang; Stefanie Mitchell; Brian G Gentry; Julie M Breitenbach; John C Drach; John Hilfinger
Journal:  Bioorg Med Chem Lett       Date:  2008-12-10       Impact factor: 2.823

10.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.